Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Novo Nordisk

With a few exceptions, healthcare stocks have had a rough go of it in 2023. The Standards and Practices (S&P) 500 Healthcare Index is down 5% year to date, versus a 13% increase in the benchmark S&P 500 index.

3 Healthcare Stocks to Invest in for a Big Shot of Gains

Gilead Sciences

Haleon PLC

Merck

Novartis

West Pharmaceutical Services

Zimmer Biomet Hlds

One of my favorite sectors will always be the healthcare sector. It is practically a basic need for all human beings and is always in constant development and growth.

7 Healthcare Stocks to invest in for a Healthy Future

Celsius Holdings

Dominion Energy

Coca-Cola

Morgan Stanley

Patterson Companies

Visa

Investors are worried that the stock market's first-half performance in 2023 is reversing. It's unclear what part of the business cycle we are currently in.

7 Resilient Stocks Poised to Prosper in Any Market Condition

EssilorLuxottica SA

Investors looking for stocks in the Medical - Products sector might want to consider either Medtronic (MDT) or EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks offers value investors a better bang for their buck right now?

MDT or ESLOY: Which Is the Better Value Stock Right Now?

Kellogg

WK Kellogg Co

Spin-offs are almost always pitched as a way to create value for shareholders, but that's not always what happens. Kellogg recently broke into two companies, Kellanova and WK Kellogg.

You Can't Control Spin-Offs, but You Can Control What You Do About Them

Ambev

Adyen NV

Bayer AG

British American Tobacco

Anheuser-Busch InBev

Diageo

FANUC Corp

GlaxoSmithKline

Imperial Brands PLC

JD.com

Novozymes A/S

Omron Corp

Roche Holding AG

Safran SA

Shimano Inc

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The October 2023 Heat Map

Viatris

Medtronic offers impressive innovation, a strong position in healthcare, and an outstanding dividend history. Viatris is undergoing important changes that should lead to stronger financial results in the medium term.

2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip

General Motors

H&R Block

Occidental Petroleum

Banco Santander

Whirlpool

Nintendo

If you're searching for the best value stocks to buy now, look no further. Value stocks are back in the spotlight.

7 Value Stocks Getting Ready to Vault Higher

Johnson & Johnson

Teladoc

The healthcare industry is full of manual processes that could benefit from AI. AI can help improve outcomes for patients while also growing revenue for businesses.

3 Ways AI Can Help Healthcare Companies Grow

AbbVie

Cardinal Health

CVS Health

UnitedHealth Group

Facing an uncertain market environment, investors ought to consider the top healthcare stocks that pay dividends. Sure, the Federal Reserve may be in a position to facilitate a soft landing for the economy, per bullish analysts.

7 Top Healthcare Stocks That Pay Dividends

Medtronic's (MDT) partnership will enable teachers to improve their skill set, boosting student opportunities to pursue STEM careers in corporate America.

Medtronic (MDT) to Launch Academic R&D Grants With New Pact

Comcast

Ecolab

Estee Lauder

Intercontinental Exchange

Kenvue

Altria

Pfizer

Raytheon Technologies

U.S. Bancorp

Wells Fargo

Yum China Hlds

There's a bright side to the S&P 500's recent slide. Some stocks are set up for likely gains, at least according to a Morningstar strategist.

Morningstar Says Stocks Are 8% Undervalued — Likes These 13 Best

CHICAGO--(BUSINESS WIRE)-- #augmentedreality--Augmedics, a pioneer in augmented reality (AR) surgical navigation, today announced the appointment of Tal Davidson, MD as Vice President, Research & Development. Davidson was most recently AI Research Director and Site Lead for Medtronic's Visionsense, the R&D site leading the development of intraoperative visualization and AI opportunities in minimal invasive surgery central to Medtronic's OR of the Future strategic initiative. The news comes a month after Au.

Augmedics adds Medtronic AI expert as VP R&D

Apple

Amazon

Salesforce

Microsoft

Palantir Technologies

In the dynamic world of investing, there's always a buzz surrounding “smart money” stocks. This excitement isn't just about fleeting market trends; it's rooted in the savvy market decisions made by individuals with incredible financial acumen.

7 ‘Smart Money' Stocks Set to Explode Higher

Medtronic is a leading healthcare technology company specializing in devices to treat prevalent illnesses such as diabetes, cardiovascular disease, and neurological disorders. The aging population in countries like South Korea, Japan, Italy, Greece, and Germany is driving increased demand for pacemakers and other Medtronic products. Medtronic's revenue was $7.7 billion in the first quarter of fiscal 2024, an increase of 4.5% year-over-year.

Unveiling Medtronic: The Hidden Gem Among Dividend Aristocrats

News for Medtronic Stock (MDT)